Moderate

Chronic / fibrotic hypersensitivity pneumonitis — management

fibrotic HP · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Fibrotic hypersensitivity pneumonitis results from chronic inhaled antigen exposure (birds, moulds, agricultural dusts) causing immune-mediated interstitial fibrosis. Antigen avoidance is central; immunosuppression and antifibrotics are used for inflammatory and progressive fibrotic phenotypes respectively.

Red flags

  • Rapidly progressive dyspnoea / acute exacerbation
  • Resting hypoxaemia
  • Weight loss suggesting alternative diagnosis
  • Continued antigen exposure despite advice

Assessment

Differential diagnosis

  • Idiopathic pulmonary fibrosis
  • Connective-tissue-disease ILD
  • Sarcoidosis
  • Drug-induced ILD
  • Non-specific interstitial pneumonia
  • Chronic pulmonary infection

Investigations

  • HRCT (mosaic attenuation, air trapping, centrilobular nodules, upper/mid fibrosis)
  • Detailed exposure history and specific IgG precipitins to suspected antigens
  • Spirometry/lung volumes with DLCO (restriction, low transfer)
  • Bronchoalveolar lavage lymphocytosis
  • Serial inspiratory/expiratory CT for air trapping
  • MDT discussion +/- surgical/transbronchial lung cryobiopsy when diagnosis unclear

Management

  • Take an exhaustive exposure history (birds, feather bedding, mould, hot tubs, farming, metalworking fluids)
  • Characterise HRCT pattern and assess for fibrosis and air trapping
  • Confirm with BAL lymphocytosis and antigen-specific IgG where possible
  • Discuss at an ILD MDT to reach a confident diagnosis and phenotype
  • Identify and permanently eliminate the causative antigen (remediation, remove birds, change environment)
  • Treat predominantly inflammatory disease with corticosteroids +/- steroid-sparing immunosuppression
  • Start antifibrotic therapy for a progressive fibrotic phenotype
  • Provide supportive care: pulmonary rehab, oxygen assessment, vaccination, comorbidity management
  • Monitor lung function and HRCT for progression despite avoidance
  • Refer progressive disease for lung transplant assessment

Drugs & doses

Prednisolone 0.5 mg/kg/day PO then taper over weeks for inflammatory disease
Mycophenolate mofetil 1 g PO twice daily as steroid-sparing agent
Azathioprine 1-2 mg/kg PO once daily alternative
Nintedanib 150 mg PO twice daily for progressive pulmonary fibrosis

Disposition

ILD specialist clinic / MDT; occupational-environmental remediation support; transplant referral for progressive disease.

Complications & pitfalls

  • Progressive pulmonary fibrosis and respiratory failure
  • Pulmonary hypertension
  • Acute exacerbation with high mortality
  • Immunosuppression-related infection

Exam pearls

  • A clear inciting antigen is identified in only ~50% — absence does not exclude HP
  • Antigen avoidance improves survival and is the single most important intervention
  • A UIP-like fibrotic pattern on HRCT carries an IPF-like prognosis
  • Nintedanib slows decline in progressive fibrosing HP regardless of underlying cause

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.